COVID-19: лечение и профилактика
Назад
https://www.embopress.org/doi/full/10.15252/emmm.202114122
The golden hamster model reproduces a moderate-to-severe COVID-19 in humans, with a clinical phase lasting 5–6 days post-infection followed by a complete recovery by 2 weeks post-infection, with no death occurring. The viral titers and viral RNA loads in the airways of infected animals are elevated after 2–4 days post-infection, but they drastically drop by 7 days post-infection (Chan et al, 2020; Sia et al, 2020; de Melo et al, 2021).
Ivermectin might then be considered as promising therapeutic agent against COVID-19 with no impact on SARS-CoV-2 replication but alleviating inflammation and ensuing symptoms.
IVM has been shown to be active beyond its anti-parasitic activity in a wide variety of pathologies, including cancer, allergy, and viral infections (Laing et al, 2017)
Не знаю, может быть это уже тут было. Институт молекулярной медицины.